Form 4: Corcept Therapeutics Director Exercises Options and Transfers Shares

Director James N. Wilson exercised stock options and transferred shares, resulting in changes to his beneficial ownership of Corcept Therapeutics stock.

Summary

• James N. Wilson, a director at Corcept Therapeutics, exercised stock options to acquire 250,000 shares of common stock at a price of $3.29 per share on January 22, 2025.
• To cover the exercise price and tax liabilities, 103,258 shares were withheld at a price of $59.03 per share.
• Following the exercise and withholding, 146,742 shares were transferred to the James N. Wilson and Pamela D. Wilson Trust without consideration.
• After these transactions, Mr. Wilson directly owns no shares, but indirectly owns 1,452,968 shares through the James N. Wilson and Pamela D. Wilson Trust and 901,067 shares through James and Pamela Wilson Family Partners.
• The stock options were fully exercisable on January 22, 2025, and the underlying shares are common stock.

Sentiment

Score: 5

Explanation: The document is a routine filing related to stock option exercises and share transfers by a director. It doesn't indicate any positive or negative sentiment.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who have made transactions in their company's stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, and this filing is consistent with the requirements of the SEC.
• The transactions are typical for directors who have stock options as part of their compensation package.
• The withholding of shares to cover taxes and exercise costs is a common practice.

Stakeholder Impact

• The transactions have a minor impact on the overall share structure of the company.
• The filing provides transparency to shareholders regarding insider transactions.

Key Dates

Keywords

stock options, beneficial ownership, insider trading, share transfer, Corcept Therapeutics, CORT, director, equity